PAVmed Inc. to Hold Business Update Conference Call on August 17th
August 09 2017 - 7:30AM
Business Wire
PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly
differentiated, multi-product medical device company, today
announced that the Company will host a conference call on Thursday,
August 17, 2017 at 4:30 p.m. Eastern time. During this call Lishan
Aklog, M.D., the Company’s Chairman and Chief Executive Officer,
will provide a business update including an overview of the
Company’s near-term milestones and growth strategy. In addition,
Dennis McGrath, the Company’s Chief Financial Officer, will discuss
second quarter 2017 financial results, which will be announced on
August 14, 2017 after the close of the market.
To access the conference call, U.S.-based listeners should dial
(888) 803-5993 and international listeners should dial (706)
634-5454. All listeners should provide the following passcode:
64738878. Individuals interested in listening to the live
conference call via the Internet may do so by visiting the
Company’s website at www.pavmed.com.
Following the conclusion of the conference call, a replay will
be available through August 23, 2017 and can be accessed by dialing
(855) 859-2056 from within the U.S. or (404) 537-3406 from outside
the U.S. All listeners should provide passcode: 64738878. The
webcast will be available for 90 days on the Company’s website at
www.pavmed.com.
About PAVmed Inc.
PAVmed Inc. (Nasdaq: PAVM, PAVMW) is a highly differentiated,
multi-product medical device company employing a unique business
model designed to advance products from concept to
commercialization much more rapidly and with significantly less
capital than the typical medical device company. This proprietary
model enables PAVmed to pursue an expanding multi-product pipeline
strategy with a view to enhancing and accelerating value creation.
PAVmed’s diversified pipeline of products address unmet clinical
needs, have attractive regulatory pathways and market opportunities
and encompass a broad spectrum of clinical areas including carpal
tunnel syndrome (CarpX™), medical infusions (NextFlo™ and
NextCath™), interventional radiology (PortIO™ and NextCath), tissue
ablation and cardiovascular intervention (Caldus™) and pediatric
ear infections (DisappEAR™).
Safe Harbor Statement
This press release includes forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements, based upon the current beliefs and expectations of the
Company’s management, are subject to risks and uncertainties, which
could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences
include, among other things, the uncertainties inherent in research
and development, including the cost and time required advance our
products to regulatory submission; whether regulatory authorities
will be satisfied with the design of and results from our
pre‐clinical studies; whether and when our products are cleared by
regulatory authorities; market acceptance of our products once
cleared and commercialized; our ability to raise additional funding
and other competitive developments. PAVmed has not yet received
clearance from the FDA or other regulatory body to market any of
its products. New risks and uncertainties may arise from time to
time and are difficult to predict. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item IA, “Risk Factors,” in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Reports on Form 10-Q filed by us after
our most recent Annual Report. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170809005180/en/
InvestorsLHA Investor RelationsKim
Sutton Golodetz, 212-838-3777kgolodetz@lhai.comorinfo@pavmed.comorMediaRooney PartnersKate Barrette,
212-223-0561kbarrette@rooneyco.com
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Apr 2023 to Apr 2024